UCB and Novartis have entered into a licensing agreement for cardiovascular and diabetes products in Germany.
Under the agreement, UCB has extended commercial rights for the German market to the cardiovascular medication Provas (valsartan) beyond 2011. Also, it has licensed in commercial rights for two line extensions, Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT).
Dafiro HCT is for the treatment of hypertension with a combination of three compounds. In addition, UCB will co-commercialize the two new oral anti-diabetics – Jalra and Icandra.
Willy Cnops, vice president and managing director at UCB Germany, said: With this agreement we are building on our strengths in Germany. We are extending our cardiovascular and metabolic product portfolio with the treatment options to date in line with UCB’s ambitions to offer the best medicines to our patients.